title: Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
authors.forename: Vadim
authors.initials: V
authors.lastname: Ivanov
authors.forename: Emeline
authors.initials: E
authors.lastname: Tabouret
authors.forename: Guillaume
authors.initials: G
authors.lastname: Chuto
authors.forename: Bruno
authors.initials: B
authors.lastname: Chetaille
authors.forename: Hacène
authors.initials: H
authors.lastname: Fezoui
authors.forename: Diane
authors.initials: D
authors.lastname: Coso
authors.forename: Jerome
authors.initials: J
authors.lastname: Rey
authors.forename: Therese
authors.initials: T
authors.lastname: Aurran-Schleinitz
authors.forename: Jean Marc
authors.initials: JM
authors.lastname: Schiano
authors.forename: Anne Marie
authors.initials: AM
authors.lastname: Stoppa
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Reda
authors.initials: R
authors.lastname: Bouabdallah
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D000077269:Lenalidomide; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D000069283:Rituximab; D016879:Salvage Therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide